Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Abstract Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. Methods Postmenopausal women with ER...

Full description

Bibliographic Details
Main Authors: Wei Wu, Jiewen Chen, Heran Deng, Liang Jin, Zhanghai He, Nanyan Rao, Yan Nie, Yandan Yao, Yaping Yang, Fengxi Su, Jieqiong Liu
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Randomized neoadjuvant pilot trial
Everolimus plus letrozole
Fluorouracil
Epirubicin and cyclophosphamide (FEC)
ER-positive and HER2-negative breast cancer
Online Access:https://doi.org/10.1186/s12885-021-08612-y

Internet

https://doi.org/10.1186/s12885-021-08612-y

Similar Items